• Z Li, R J Willke, L A Pinto, B E Rittenhouse, M J Rybak, A M Pleil, C W Crouch, B Hafkin, and H A Glick.
• Global Outcomes Research, Pharmacia Corporation, Peapack, New Jersey, USA.
• Pharmacotherapy. 2001 Mar 1;21(3):263-74.

Study ObjectiveTo compare hospital length of stay (LOS), weekly discharges, and days of antibiotic treatment with linezolid (intravenous with oral follow-up) and vancomycin (intravenous only).DesignMultinational, randomized, phase III trial.SettingsHospitals in North America, Latin America, and Europe.PatientsFour hundred sixty hospitalized patients with infections of known or suspected methicillin-resistant Staphylococcus species.InterventionAdministration of linezolid or vancomycin.Measurements And Main ResultsFor linezolid recipients, median LOS was 5 and 8 days shorter (p=0.05 and 0.003) in the complicated skin and soft tissue infection intent-to-treat (230 patients) and clinically evaluable (144) samples, and slightly but not significantly shorter in the overall intent-to-treat (460) and clinically evaluable (254) samples. In all samples, linezolid recipients had more discharges in the first week of treatment and fewer days of intravenous therapy than vancomycin recipients.ConclusionOur results support linezolid's ability to reduce medical resource use.

37 keywords...

hide…